Inogen (INGN) remains unprofitable, with losses widening at a 31.9% annual rate over the past five years. Forecasts show its net profit margin is expected to stay negative for at least three more ...
Inogen Inc (NASDAQ:INGN) achieved its 6th consecutive quarter of mid-single-digit growth, with approximately $92 million in revenue. The company reported a 19% increase in overall unit volumes, driven ...
Inogen Inc (NASDAQ:INGN) released its Q2 2025 financial results on August 7, 2025, revealing continued revenue growth despite mixed performance across business segments. The company’s stock closed at ...
Inogen Inc. (INGN) reported its first-quarter 2025 earnings, showcasing a notable improvement in financial performance compared to prior periods. The company posted a narrower-than-expected loss per ...
GOLETA, Calif.--(BUSINESS WIRE)-- Inogen, Inc. (INGN) (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced preliminary ...
カリフォルニア州ゴレタ拠点の呼吸器系医療技術企業（登記はデラウェア州）。 慢性呼吸器疾患に対応する酸素補給療法向け携帯型酸素濃縮器（POC）や気道クリアランス治療用製品などの開発、製造、販売を手がける。POC「Inogen Rove」「Inogen One」システム ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する